Immune Checkpoint Inhibitors in Cancer Patients with Autoimmune Disease: Safety and Efficacy

Overview

Journal Hum Vaccin Immunother

Date 2025 Feb 2

PMID 39894761

Authors

Jiayuan Le

Yuming Sun

Guangtong Deng

Yating Dian

Yanli Xie

Furong Zeng

Affiliations

Soon will be listed here.

Abstract

The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. Hence, we conducted a meta-analysis on safety and efficacy of ICIs in cancer patients with preexisting autoimmune diseases to provide further insights. PubMed, EMBASE, and Cochrane Library were systematically searched until December 20, 2024. The main summary measures used were pooled rate and risk ratio (RR) with 95% confidential interval (CI), which were analyzed using R statistic software. A total of 52 articles were included in the study. When cancer patients with preexisting autoimmune diseases received ICIs treatment, the overall incidence was 0.610 (95% CI: 0.531-0.686) for any grade irAEs, 0.295 (95% CI: 0.248-0.343) for flares, 0.325 (95% CI: 0.258-0.396) for de novo irAEs, 0.238 (95% CI: 0.174-0.309) for grade ≥3 irAEs, and 0.143 (95% CI: 0.109-0.180) for discontinuation due to immunotoxicity. Compared with those without autoimmune diseases, cancer patients with autoimmune diseases experienced a higher risk of any-grade irAEs (RR: 1.23, 95% CI: 1.12-1.35) and discontinuation due to immunotoxicity (1.40, 95% CI: 1.11-1.78). However, no statistically significant differences were observed in the incidence of grade ≥3 irAEs, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between the two groups. During ICIs treatment, irAEs are common among cancer patients with autoimmune diseases, but severe irAEs is relatively low. ICIs are effective in this population, but should be strictly monitored when used to avoid immunotoxicity.

References

Han C, Fitzgerald C, Lee M, Valero C, Gonen M, Shoushtari A . Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. JAMA Oncol. 2022; 8(9):1352-1354. PMC: 9264212. DOI: 10.1001/jamaoncol.2022.2081. View

Schadendorf D, Ascierto P, Haanen J, Espinosa E, Demidov L, Garbe C . Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019; 121:144-153. DOI: 10.1016/j.ejca.2019.08.014. View

Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff J . Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018; 25(5):e403-e410. PMC: 6209550. DOI: 10.3747/co.25.4047. View

Leonardi G, Gainor J, Altan M, Kravets S, Dahlberg S, Gedmintas L . Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018; 36(19):1905-1912. PMC: 6553840. DOI: 10.1200/JCO.2017.77.0305. View

Loriot Y, Sternberg C, Castellano D, Oosting S, Dumez H, Huddart R . Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer. 2020; 138:202-211. DOI: 10.1016/j.ejca.2020.07.023. View

Yeung C, Kartolo A, Holstead R, Moffat G, Hanna L, Hopman W . Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. J Immunother. 2021; 44(9):362-370. DOI: 10.1097/CJI.0000000000000377. View

Kehl K, Yang S, Awad M, Palmer N, Kohane I, Schrag D . Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019; 68(6):917-926. PMC: 11028270. DOI: 10.1007/s00262-019-02321-z. View

Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K . Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother. 2021; 70(8):2197-2207. PMC: 10992076. DOI: 10.1007/s00262-021-02851-5. View

Ardizzoni A, Azevedo S, Rubio-Viqueira B, Rodriguez-Abreu D, Alatorre-Alexander J, Smit H . Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer. 2021; 9(3). PMC: 7978274. DOI: 10.1136/jitc-2020-001865. View

10.

Dougan M, Luoma A, Dougan S, Wucherpfennig K . Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021; 184(6):1575-1588. PMC: 7979511. DOI: 10.1016/j.cell.2021.02.011. View

11.

Abdel-Wahab N, Shah M, Lopez-Olivo M, Suarez-Almazor M . Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Ann Intern Med. 2018; 169(2):133-134. DOI: 10.7326/L18-0209. View

12.

Sleiman J, Wei W, Shah R, Faisal M, Philpott J, Funchain P . Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. J Immunother Cancer. 2021; 9(6). PMC: 8220461. DOI: 10.1136/jitc-2021-002567. View

13.

Chavaz L, Guyon D, Boespflug A, Cauquil C, Michot J . Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis. Eur J Cancer. 2023; 189:112928. DOI: 10.1016/j.ejca.2023.05.016. View

14.

Fountzilas E, Lampaki S, Koliou G, Koumarianou A, Levva S, Vagionas A . Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother. 2021; 71(2):327-337. PMC: 8783878. DOI: 10.1007/s00262-021-02985-6. View

15.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

16.

Meric-Bernstam F, Larkin J, Tabernero J, Bonini C . Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2020; 397(10278):1010-1022. DOI: 10.1016/S0140-6736(20)32598-8. View

17.

Tang K, Tiu B, Wan G, Zhang S, Nguyen N, Leung B . Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. J Natl Cancer Inst. 2022; 114(8):1200-1202. PMC: 9360452. DOI: 10.1093/jnci/djac046. View

18.

Huang Y, Cai X, Mai W, Li M, Hu Y . Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016; 355:i5953. PMC: 5121106. DOI: 10.1136/bmj.i5953. View

19.

Richter M, Pinkston O, Kottschade L, Finnes H, Markovic S, Thanarajasingam U . Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol. 2018; 70(3):356-360. DOI: 10.1002/art.40397. View

20.

Presotto E, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N . Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest. 2019; 43(3):337-345. DOI: 10.1007/s40618-019-01112-8. View